What does the future hold for the management of chronic heart failure?

European Heart Journal, Supplement

Volumn 8, Issue C, 2006, Pages

  Vanoli, Emilio ^a,b,c   Adamson, Philip B ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Policlinico di Monza   (Italy)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Adrenergic blockade; Autonomic nervous system; Heart failure; Sudden death

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL; NERVE GROWTH FACTOR; NEUROMODULIN; NORADRENALIN; NORADRENALIN TRANSPORTER; NORADRENALIN TRANSPORTER MOLECULE UPTAKE 1; RAMIPRIL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARRHYTHMOGENESIS; CATECHOLAMINE RELEASE; CONFERENCE PAPER; DOG; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART REPOLARIZATION; HEART VENTRICLE; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; HUMAN; MORTALITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; RISK REDUCTION; SUDDEN DEATH; SYSTEMATIC REVIEW;

EID: 33750094540     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sul014     Document Type: Conference Paper

References (55)

1. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998; 98:2334-2351.
2. Richter S, Duray G, Gronefeld G, C WI, S HH. Prevention of sudden cardiac death: lessons from recent controlled trials. Circ J 2005;69:625-629.
3. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997;30:1500-1505.
4. Lown B. Sudden cardiac death: the major challenge confronting contemporary cardiology. Am J Cardiol 1979;43:313-328.
5. American Heart Association. Heart disease and stroke statistics-2005 update. http://www.americanheart.org/downloadable/heart/ 1105390918119HDSStats2005Update.pdf (December 2005).
6. McMurray J, Stewart S. The burden of heart failure. Eur Heart J 2003;5(Suppl. I):I3-I13.
7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2009.
8. Cleland JGF, Chattopadhyay S, Khand A, Houghton T, Kaye GC. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev 2002;7:229-242.
9. Vanoli E, Funck-Brentano C, Hansen S, Hohnloser SH. Effect of bisoprolol on nocturnal sudden death in chronic heart failure. (Abstract). Circulation 1999;99(suppl.):I-783.
10. Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
11. Uretsky BF, Thygesen K, Armstrong PW et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000;102:611-616.
12. Exner DV, Reiffel JA, Epstein AE et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 1999;34:325-333.
13. Levine JH, Mellits ED, Baumgardner RA et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation 1991;84:558-566.
14. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 1999;318:1730-1737.
15. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
16. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999;33:916-923.
17. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
18. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
19. Rutherford JD, Pfeffer MA, Moye LA et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994;90:1731-1738.
20. Torp-Pedersen C, Kober L, Carlsen J. Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. Am Heart J 1996;132:235-243.
21. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997;18:41-51.
22. Willenheimer R, van Veldhuisen DJ, Silke B et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;12:2426-2435.
23. Willenheimer R, Erdmann E, Follath F et al. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. Eur J Heart Fail 2004;6:493-500.
24. Bristow MR, Ginsburg R, Umans V et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986;59:297-309.
25. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993;22:61A-71A.
26. Bristow MR, Feldman AM, Adams KF Jr, Goldstein S. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned fromthe COMET trial? J Card Fail 2003;9:444-453.
27. The Beta-blocker Evaluation of Survival (BEST) Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-1667.
28. Cohn JN, Pfeffer MA, Rouleau J et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5:659-667.
29. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI40-VI48.
30. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351:478-484.
31. Vanoli E, Adamson PB. Baroreflex sensitivity: methods, mechanisms, and prognostic value. Pacing Clin Electrophysiol 1994;17:434-445.
32. Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS Jr, Foreman RD, Schwartz PJ. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 1991;68:1471-1481.
33. De Ferrari GM, Vanoli E, Stramba-Badiale M, Hull SS Jr, Foreman RD, Schwartz PJ. Vagal reflexes and survival during acute myocardial ischemia in conscious dogs with healed myocardial infarction. Am J Physiol 1991;261:H63-H69.
34. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997; 29:709-715.
35. Sabbah HN, Stein PD, Kono T et al. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 1991;260:H1379-H1384.
36. Sabbah HN, Shimoyama H, Kono T et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-2859.
37. Sabbah HN, Goldberg AD, Schoels W et al. Spontaneous and inducible ventricular arrhythmias in a canine model of chronic heart failure: relation to haemodynamics and sympathoadrenergic activation. Eur Heart J 1992;13:1562-1572.
38. Pogwizd SM. Focal mechanisms underlying ventricular tachycardia during prolonged ischemic cardiomyopathy. Circulation 1994;90: 1441-1458.
39. Adamson PB, Vanoli E. Early autonomic and repolarization abnormalities contribute to lethal arrhythmias in chronic ischemic heart failure: characteristics of a novel heart failure model in dogs with postmyocardial infarction left ventricular dysfunction. J Am Coll Cardiol 2001;37:1741-1748.
40. Swann MH, Nakagawa H, Vanoli E, Lazzara R, Schwartz PJ, Adamson PB. Heterogeneous regional endocardial repolarization is associated with increased risk for ischemia-dependent ventricular fibrillation after myocardial infarction. J Cardiovasc Electrophysiol 2003;14:873-879.
41. Cao JM, Fishbein MC, Han JB et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 2000;101:1960-1969.
42. Miyauchi Y, Zhou S, Okuyama Y et al. Altered atrial electrical restitution and heterogeneous sympathetic hyperinnervation in hearts with chronic left ventricular myocardial infarction: implications for atrial fibrillation. Circulation 2003;108:360-366.
43. Cao JM, Chen LS, KenKnight BH et al. Nerve sprouting and sudden cardiac death. Circ Res 2000;86:816-821.
44. Zhou S, Chen LS, Miyauchi Yet al. Mechanisms of cardiac nerve sprouting after myocardial infarction in dogs. Circ Res 2004;95:76-83.
45. Bohm M, La Rosee K, Schwinger RH, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 1995;25:146-153.
46. Leineweber K, Wangemann T, Giessler C et al. Age-dependent changes of cardiac neuronal noradrenaline reuptake transporter (uptake1) in the human heart. J Am Coll Cardiol 2002;40:1459.
47. Munch G, Rosport K, Bultmann A et al. Cardiac overexpression of the norepinephrine transporter uptake-1 results in marked improvement of heart failure. Circ Res 2005;97:928-936.
48. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140.
49. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883.
50. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237.
51. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004;44:2166-2172.
52. Cleland JG, Ghosh J, Freemantle N et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004;6:501-508.
53. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004;292:2874-2879.
54. Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-2150.
55. Proclemer A, Ghidina M, Cicuttini G, Gregori D, Fioretti PM. The Italian Implantable Cardioverter-Defibrillator Registry. A survey of the national activity during the years 2001-2003. Ital Heart J 2005;6:272-280.